Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Calcifediol Treatment and COVID-19-Related Outcomes
We removed this preprint due to concerns about the description of the research in this paper. This led us to initiate an investigation into this study.
Following the conclusion of an investigation into this study by the National Centre of Biomedical Research on Frailty and Healthy Aging (CIBERFES), Spain, the report concluded that: 1) In the elaboration of the manuscript and the correspondence of the authors with the Journal, there was a series of mistakes made by the authors in the qualification of the study and its description; and 2) At all times good practices for clinical research were carefully followed and in no case was the health of the patients put at any risk.
The comments that have been posted on this preprint will remain available on this page. Please note that this comment thread is now closed to further posts.
Nogués, Xavier and Ovejero, Diana and Quesada-Gomez, J. M. and Bouillon, Roger and Arenas, Dolores and Pascual, Julio and Villar-Garcia, Judith and Rial, Abora and Gimenez-Argente, Carme and Cos, ML. and Rodriguez-Morera, Jaime and Campodarve, Isabel and Guerri-Fernandez, Robert and Pineda-Moncusí, Marta and García-Giralt, Natalia, Calcifediol Treatment and COVID-19-Related Outcomes. Available at SSRN: https://ssrn.com/abstract=3771318 or http://dx.doi.org/10.2139/ssrn.3771318
